Burning Rock Biotech Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Burning Rock Biotech.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs earnings growth | 28.5% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
Recent updates
Little Excitement Around Burning Rock Biotech Limited's (NASDAQ:BNR) Revenues
Jun 21
Will Burning Rock Biotech (NASDAQ:BNR) Spend Its Cash Wisely?
Mar 25There's No Escaping Burning Rock Biotech Limited's (NASDAQ:BNR) Muted Revenues
Feb 01Burning Rock Biotech Limited (NASDAQ:BNR) Shares Could Be 24% Below Their Intrinsic Value Estimate
Jul 12Is Burning Rock Biotech (NASDAQ:BNR) In A Good Position To Deliver On Growth Plans?
Apr 28We Think Burning Rock Biotech (NASDAQ:BNR) Needs To Drive Business Growth Carefully
Dec 23Is Burning Rock Biotech (NASDAQ:BNR) In A Good Position To Invest In Growth?
Sep 20Burning Rock Biotech GAAP EPS of -$0.37 misses by $0.01, revenue of $19.5M misses by $2.94M
Aug 31Burning Rock Localizes As Investors Grow Impatient
Jun 06We're Hopeful That Burning Rock Biotech (NASDAQ:BNR) Will Use Its Cash Wisely
Mar 24Following Rough Year, Is Burning Rock Set To Turn The Corner?
Nov 17Is Burning Rock Biotech (NASDAQ:BNR) Using Debt In A Risky Way?
Aug 27A Look At The Intrinsic Value Of Burning Rock Biotech Limited (NASDAQ:BNR)
Jul 23Is Burning Rock Biotech (NASDAQ:BNR) Using Debt Sensibly?
May 13Burning Rock Biotech Expands Test Portfolio In Bid For Growth
Dec 30Burning Rock inks license pact with Oncocyte Corporation
Dec 15Burning Rock Biotech prices upsized offering of 2.243M ADSs at $25.75/ADS
Dec 04Burning Rock Biotech EPS misses by $0.08, beats on revenue
Nov 20In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Burning Rock Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2024 | 510 | -567 | -154 | -144 | N/A |
| 3/31/2024 | 521 | -590 | -192 | -183 | N/A |
| 12/31/2023 | 537 | -654 | -265 | -256 | N/A |
| 9/30/2023 | 559 | -708 | -378 | -307 | N/A |
| 6/30/2023 | 586 | -764 | -466 | -396 | N/A |
| 3/31/2023 | 570 | -895 | -496 | -426 | N/A |
| 12/31/2022 | 563 | -971 | -527 | -457 | N/A |
| 9/30/2022 | 568 | -1,006 | -715 | -501 | N/A |
| 6/30/2022 | 540 | -945 | -608 | -499 | N/A |
| 3/31/2022 | 537 | -887 | -723 | -509 | N/A |
| 12/31/2021 | 508 | -797 | -691 | -478 | N/A |
| 9/30/2021 | 492 | -702 | -536 | -456 | N/A |
| 6/30/2021 | 490 | -659 | -545 | -360 | N/A |
| 3/31/2021 | 469 | -564 | -259 | -180 | N/A |
| 12/31/2020 | 430 | -472 | -153 | -74 | N/A |
| 9/30/2020 | 387 | -450 | -79 | -33 | N/A |
| 6/30/2020 | 367 | -389 | -53 | -13 | N/A |
| 3/31/2020 | 345 | -347 | -169 | -129 | N/A |
| 12/31/2019 | 382 | -334 | -274 | -228 | N/A |
| 9/30/2019 | 358 | -268 | -214 | -208 | N/A |
| 12/31/2018 | 209 | -232 | -173 | -149 | N/A |
| 12/31/2017 | 111 | -185 | N/A | -134 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if BNR's forecast earnings growth is above the savings rate (2.5%).
Earnings vs Market: Insufficient data to determine if BNR's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if BNR's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if BNR's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if BNR's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BNR's Return on Equity is forecast to be high in 3 years time